» Articles » PMID: 26288403

Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy

Overview
Specialty Dermatology
Date 2015 Aug 20
PMID 26288403
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although various therapies used for the treatment of psoriasis are able to produce remission, yet relapses, a common problem, remains frequent. It was observed that treatment with intermittent high dose (IHD) and continuous low dose (CLD) azathioprine can produce prolonged and durable remission in psoriasis.

Aims: To see the long term effect of azathioprine pulse therapy (APT) in psoriasis.

Methods: Ten patients with psoriasis who has completed more than 5 years in remission with azathioprine pulse therapy are being taken in the study. They were given IHD azathioprine (500 mg on 3 consecutive days which is repeated every month) with CLD azathioprine (100 mg orally) daily in between IHD. The entire treatment schedule was divided into four phases. During phase I, treatment with IHD and CLD azathioprine was started and continued till complete clearance of lesions after which, patients proceeded to Phase II. In phase II, they continued to get treatment with IHD and CLD. After continued remission for a period of nine months, they entered into phase III, when the treatment with IHD was stopped, but CLD continued. If there was no recurrence after nine months of phase III treatment, CLD was also withdrawn, and patients were followed-up without any treatment (Phase IV).

Results: All 10 patients completed treatment and are in remission for more than five years without any treatment.

Conclusions: Out of 60 patients in phase IV, 10 patients were in continuous remission for more than five years, after all treatment had been stopped. Thus, azathioprine pulse therapy regimen produces prolonged remission in psoriasis.

Citing Articles

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab.

Wojcik M, Plata-Babula A, Glowaczewska A, Sirek T, Orczyk A, Malecka M Cell Cycle. 2024; 23(4):385-404.

PMID: 38557266 PMC: 11174132. DOI: 10.1080/15384101.2024.2335051.


Gene expression profile of mitogen-activated kinases and microRNAs controlling their expression in HaCaT cell culture treated with lipopolysaccharide A and cyclosporine A.

Wojcik M, Zmarzly N, Derkacz A, Kulpok-Baginski T, Blek N, Grabarek B Cell Cycle. 2024; 23(3):279-293.

PMID: 38445655 PMC: 11057563. DOI: 10.1080/15384101.2024.2320508.


Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment.

Jain H, Bhat A, Dalvi H, Godugu C, Singh S, Srivastava S Curr Res Pharmacol Drug Discov. 2021; 2:100041.

PMID: 34909670 PMC: 8663928. DOI: 10.1016/j.crphar.2021.100041.


Azathioprine: its uses in dermatology.

Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, Ocampo-Candiani J, Garza-Garza R, Gomez-Flores M An Bras Dermatol. 2020; 95(6):731-736.

PMID: 33250113 PMC: 7672387. DOI: 10.1016/j.abd.2020.05.003.


PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.

Gold L, Alonso-Llamazares J, Lacour J, Warren R, Tyring S, Kircik L Adv Ther. 2020; 37(11):4730-4753.

PMID: 32965655 PMC: 7547957. DOI: 10.1007/s12325-020-01497-6.

References
1.
Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61(3):451-85. DOI: 10.1016/j.jaad.2009.03.027. View

2.
du Vivier A, MUNRO D, Verbov J . Treatment of psoriasis with azathioprine. Br Med J. 1974; 1(5897):49-51. PMC: 1632899. DOI: 10.1136/bmj.1.5897.49. View

3.
Jain S, Sehgal V . Psoriasis and calcipotriol: an overview. Int J Dermatol. 1997; 36(4):255-8. DOI: 10.1046/j.1365-4362.1997.00030.x. View

4.
Greaves M, Dawber R . Azathioprine in psoriasis. Br Med J. 1970; 2(5703):237-8. PMC: 1700078. DOI: 10.1136/bmj.2.5703.237-b. View

5.
Lebwohl M, Abel E, Zanolli M, Koo J, Drake L . Topical therapy for psoriasis. Int J Dermatol. 1995; 34(10):673-84. View